Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
Genetic engineering drugs
Photodynamic therapy drugs
Liposomal drugs
Medical Diagnostic Products
 
Liposomal drugs
Libod® (Doxorubicin liposome)

The PEG modified liposome doxorubicin injection (Libod®) made with revolutionary Stealth technique has been approved to be listed in market by SFDA in July, 2009. It is a first and only PEG modified liposome chemotherapy drug manufactured inside China.

Libod has a new pharmacokinetic property different from conventional doxorubicin hydrochloride. The introduction of liposome carrier enhances the cycling duration of the drug to help the drug concentrate in the tumor area. The control of particle size reduces the reversed reaction of the conventional drug, such as cardiovascular toxicity, bone marrow inhibition and hair loss, while the efficacy is increased. It is a fairly better anthracene chemotherapeutic drug.

The product is a liposome reagent. Doxorubicin is embodied and sealed in PEGalated liposome carrier. The PEG protects the liposome from the recognition of MPS (mononuclear-macrophage system) and then the duration of the circulation is prolonged.

The product is a sterile, translucent, red suspension. Each vial of 10 ml, suitable for the intravenous infusion in uni-dose, contains 2 mg/ml of doxorubicin hydrochloride which is a cytotoxic anthracyclin antibiotic isolated from Streptomyces peucetius var.caesius.

The register number: State Drug Registration H20084432 (国药准字H20084432).

The indication: Used for the treatment of AIDS-related Kaposi’s sarcoma (AIDS-KS) in patients with low CD4(<200CD4lymph cell/mm3)  and various diseases of skin, mucosa and viscera.

The product is used as the first-line chemotherapeutic drug or the second-line drug for the AIDS-KS patient whose disease has progressed, also used for the patients who are intolerant to the therapy with following combinations: vincristine, bleomycin and doxorubicin (or other anthracyclin antibiotics).

The product of doxorubicin liposome injection was approved to be used in the treatment of breast cancer, ovarian cancer and bone marrow cancer overseas.

Strength: 20mg/10ml/vial

 


This page outlines FDZJ drug development portfolio. The content of the portfolio will change over time as new compounds progress from discovery to development. Due to the nature of the drug development process, it is not unusual for some compounds, especially those in early stages of investigation, to be terminated as they progress through development. For competitive reasons, some projects have not been disclosed and some project types may not have been identified.

Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2015-0015    沪ICP备10027510号-1